Characterizations of clinical isolates of Clostridium difficile by toxin genotypes and by susceptibility to 12 antimicrobial agents, including fidaxomicin (OPT-80) and rifaximin: A multicenter study in Taiwan

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 7, 2012, Pages 3943-3949

  Liao, Chun Hsing ^a   Ko, Wen Chien ^b   Lu, Jang Jih ^c   Hsueh, Po Ren ^d  

^a FAR EASTERN MEMORIAL HOSPITAL   (Taiwan)

^b NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

^c CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^d NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CIPROFLOXACIN; CLINDAMYCIN; CLOSTRIDIUM DIFFICILE TOXIN A; DAPTOMYCIN; DNA TOPOISOMERASE (ATP HYDROLYSING) A; DNA TOPOISOMERASE (ATP HYDROLYSING) B; FIDAXOMICIN; GEMIFLOXACIN; LEVOFLOXACIN; METRONIDAZOLE; MOXIFLOXACIN; NEMONOXACIN; RIFAXIMIN; TIGECYCLINE; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; CLOSTRIDIUM DIFFICILE; GENE MUTATION; GENOTYPE; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; TAIWAN;

ANTI-INFECTIVE AGENTS; AZA COMPOUNDS; BACTERIAL PROTEINS; CLOSTRIDIUM DIFFICILE; FLUOROQUINOLONES; GLYCOSIDES; MICROBIAL SENSITIVITY TESTS; NAPHTHYRIDINES; OFLOXACIN; QUINOLINES; RIFAMYCINS; TAIWAN; VANCOMYCIN;

EID: 84862525707     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00191-12     Document Type: Article

References (40)

1. Ackermann G, et al. 2001. Resistance to moxifloxacin in toxigenic Clostridium difficile isolates is associated with mutations in gyrA. Antimicrob. Agents Chemother. 45:2348-2353. (Pubitemid 32664477)
2. Al-Nassir WN, et al. 2008. Both oral metronidazole and oral vancomycin promote persistent overgrowth of vancomycin-resistant enterococci during treatment of Clostridium difficile-associated disease. Antimicrob. Agents Chemother. 52:2403-2406. (Pubitemid 351915669)
3. Baines SD, et al. 2008. Emergence of reduced susceptibility to metronidazole in Clostridium difficile. J. Antimicrob. Chemother. 62:1046-1052.
4. Bauer MP, Kuijper EJ, van Dissel JT. 2009. European Society of Clinical Microbiology and Infectious Diseases (ESCMID): treatment guidance document for Clostridium difficile infection (CDI). Clin. Microbiol. Infect. 15:1067-1079.
5. Chung CH, et al. 2010. Clostridium difficile infection at a medical center in southern Taiwan: incidence, clinical features and prognosis. J. Microbiol. Immunol. Infect. 43:119-125.
6. Clinical and Laboratory Standards Institute. 2007. Methods for antimicrobial susceptibility testing of anaerobic bacteria. Approved standard M11-A7, 7th ed. Clinical and Laboratory Standards Institute, Wayne, PA.
7. Cohen SH, et al. 2010. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect. Control Hosp. Epidemiol. 31:431-455.
8. Deneve C, et al. 2009. Effects of subinhibitory concentrations of antibiotics on colonization factor expression by moxifloxacin-susceptible and moxifloxacin-resistant Clostridium difficile strains. Antimicrob. Agents Chemother. 53:5155-5162.
9. Dingle KE, et al. 2011. Clinical Clostridium difficile: clonality and pathogenicity locus diversity. PLoS One 6:e19993. doi:10.1371/journal.pone. 0019993.
10. Dridi L, Tankovic J, Burghoffer B, Barbut F, Petit JC. 2002. gyrA and gyrB mutations are implicated in cross-resistance to ciprofloxacin and moxifloxacin in Clostridium difficile. Antimicrob. Agents Chemother. 46:3418-3421. (Pubitemid 35192906)
11. Drudy D, Kyne L, O'Mahony R, Fanning S. 2007. gyrA mutations in fluoroquinolone-resistant Clostridium difficile PCR-027. Emerg. Infect. Dis. 13:504-505. (Pubitemid 46348149)
12. Drudy D, et al. 2006. High-level resistance to moxifloxacin and gatifloxacin associated with a novel mutation in gyrB in toxin-A-negative, toxin-B-positive Clostridium difficile. J. Antimicrob. Chemother. 58:1264-1267. (Pubitemid 44884150)
13. European Committee on Antimicrobial Susceptibility Testing. 2011. Clinical breakpoint tables, version 1.3. European Committee on Antimicrobial Susceptibility Testing, London, United Kingdom. http://www.eucast.org/eucast- susceptibility-testing/breakpoints/. Accessed 21 February 2012.
14. Garey KW, et al. 2011. A randomized, double-blind, placebo-controlled pilot study to assess the ability of rifaximin to prevent recurrent diarrhoea in patients with Clostridium difficile infection. J. Antimicrob. Chemother. 66:2850-2855.
15. Garey KW, Jiang ZD, Bellard A, Dupont HL. 2009. Rifaximin in treatment of recurrent Clostridium difficile-associated diarrhea: an uncontrolled pilot study. J. Clin. Gastroenterol. 43:91-93.
16. Goldstein EJ, et al. 2011. Comparative susceptibilities to fidaxomicin (OPT-80) of isolates collected at baseline, recurrence, and failure from patients in two phase III trials of fidaxomicin against Clostridium difficile infection. Antimicrob. Agents Chemother. 55:5194-5199.
17. Gonzales M, et al. 2010. Faecal pharmacokinetics of orally administered vancomycin in patients with suspected Clostridium difficile infection. BMC Infect. Dis. 10:363.
18. Hardesty JS, Juang P. 2011. Fidaxomicin: a macrocyclic antibiotic for the treatment of Clostridium difficile infection. Pharmacotherapy 31:877-886.
19. Hernandez A, Sanchez MB, Martinez JL. 2011. Quinolone resistance: much more than predicted. Front. Microbiol. 2:22.
20. Hsu MS, Wang JT, Huang WK, Liu YC, Chang SC. 2006. Prevalence and clinical features of Clostridium difficile-associated diarrhea in a tertiary hospital in northern Taiwan. J. Microbiol. Immunol. Infect. 39:242-248.
21. Huang H, Weintraub A, Fang H, Nord CE. 2009. Antimicrobial resistance in Clostridium difficile. Int. J. Antimicrob. Agents 34:516-522.
22. Huang H, et al. 2010. Antimicrobial susceptibility and heteroresistance in Chinese Clostridium difficile strains. Anaerobe 16:633-645.
23. Kim H, et al. 2010. Investigation of toxin gene diversity, molecular epidemiology, and antimicrobial resistance of Clostridium difficile isolated from 12 hospitals in South Korea. Korean J. Lab. Med. 30:491-497.
24. Kuijper EJ, et al. 2007. Update of Clostridium difficile-associated disease due to PCR ribotype 027 in Europe. Euro Surveill. 12:E1-E2.
25. Lee YC, et al. 28 December 2011. Changing incidence and clinical manifestations of Clostridium difficile-associated diarrhea detected by combination of glutamate dehydrogenase and toxin assay in Northern Taiwan. J. Microbiol. Immunol. Infect. [Epub ahead of print.] doi:10.1016/j.jmii.2011.12. 001.
26. Lin YC, et al. 2011. Antimicrobial susceptibilities and molecular epidemiology of clinical isolates of Clostridium difficile in Taiwan. Antimicrob. Agents Chemother. 55:1701170-1701175.
27. McDonald LC, et al. 2005. An epidemic, toxin gene-variant strain of Clostridium difficile. N. Engl. J. Med. 353:2433-2441. (Pubitemid 41770164)
28. Miller BA, Chen LF, Sexton DJ, Anderson DJ. 2011. Comparison of the burdens of hospital-onset, healthcare facility-associated Clostridium difficile infection and of healthcare-associated infection due to methicillin-resistant Staphylococcus aureus in community hospitals. Infect. Control Hosp. Epidemiol. 32:387-390.
29. Miller M, et al. 2010. Health care-associated Clostridium difficile infection in Canada: patient age and infecting strain type are highly predictive of severe outcome and mortality. Clin. Infect. Dis. 50:194-201.
30. Musher DM, et al. 2005. Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole. Clin. Infect. Dis. 40:1586-1590. (Pubitemid 40720807)
31. O'Connor JR, Johnson S, Gerding DN. 2009. Clostridium difficile infection caused by the epidemic BI/NAP1/027 strain. Gastroenterology 136:1913-1924.
32. Pepin J, Valiquette L, Cossette B. 2005. Mortality attributable to nosocomial Clostridium difficile-associated disease during an epidemic caused by a hypervirulent strain in Quebec. CMAJ 173:1037-1042.
33. Pituch H, et al. 2007. Toxin profiles and resistances to macrolides and newer fluoroquinolones as epidemicity determinants of clinical isolates of Clostridium difficile from Warsaw, Poland. J. Clin. Microbiol. 45:1607-1610. (Pubitemid 46762420)
34. Rodriguez-Martinez JM, et al. 2008. Qnr-like pentapeptide repeat proteins in Gram-positive bacteria. J. Antimicrob. Chemother. 61:1240-1243. (Pubitemid 351753588)
35. Spigaglia P, Barbanti F, Dionisi AM, Mastrantonio P. 2010. Clostridium difficile isolates resistant to fluoroquinolones in Italy: emergence of PCR ribotype 018. J. Clin. Microbiol. 48:2892-2896.
36. Spigaglia P, et al. 2008. Fluoroquinolone resistance in Clostridium difficile isolates from a prospective study of C. difficile infections in Europe. J. Med. Microbiol. 57:784-789. (Pubitemid 351842073)
37. Srivastava A, et al. 2011. New target for inhibition of bacterial RNA polymerase: 'switch region.' Curr. Opin. Microbiol. 14:532-543.
38. Walkty A, et al. 2010. Molecular characterization of moxifloxacin resistance from Canadian Clostridium difficile clinical isolates. Diagn. Microbiol. Infect. Dis. 66:419-424.
39. Warny M, et al. 2005. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet 366:1079-1084. (Pubitemid 41338761)
40. Zar FA, Bakkanagari SR, Moorthi KM, Davis MB. 2007. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin. Infect. Dis. 45:302-307. (Pubitemid 47101025)